Search
Ofev-LongForm.pdf
Pradaxa-LongForm.pdf
synjardy-XR-LongForm.pdf
Tradjenta-LongForm.pdf
Trijardy-XR-LongForm.pdf
For Your SweetHeart Survey
For Your SweetHeart | Infographic
For Your SweetHeart | Campaign Facts
biah-us-overview-for-usda
Synjardy® (empagliflozin/metformin) Factsheet | PDF
PAP Eligibility Information
State of Connecticut Information
Dress For Your Day Guidelines
Advancing green chemistry for more sustainable medicines
By applying the principles of eco-design and green chemistry, we developed an innovative manufacturing process with reduced environmental footprint.
Top-line Phase II Data for treatment of MASH
Boehringer Ingelheim and Zealand Pharma announced top-line Phase II data for treatment of metabolic dysfuntion-associated steatohepatitis (MASH).
New effort to help improve C-R-M health outcomes
Boehringer Ingelheim sponsors American Heart Association's Cardiovascular Kidney Metabolic Health Intiative (CKMH)
Swine Vaccine Combo for Two Diseases | Boehringer Ingelheim US
Click here to read more on the launch of the Boehringer Ingelheim innovative vaccine combination, protecting US swine from two viruses in one shot.
Internal Teat Sealant for Dairy Cows | Boehringer Ingelheim US
Boehringer Ingelheim adds internal teat sealant to their dairy mastitis portfolio, with a more ergonomic design and improved removal process.
PAP Program Sales Force Info Flashcard
PAP Program information
Spanish-Enrollment-Form_0.pdf
EDITABLE-Spanish-Enrollment-form_3.pdf
INBUILD® meets primary endpoint: study evaluated Ofev® in patients across a range of progressive fibrosing interstitial lung diseases
INBUILD® meets primary endpoint: study evaluated Ofev® in patients across a range of progressive fibrosing interstitial lung diseases
New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status
New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status